Merck Wins FDA Approval for First Oral PCSK9 Cholesterol Pill
Product·1 article across 1 outlet·↩ Updated
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Merck & Co. has secured US regulatory approval for Lipfendra, a new oral cholesterol pill that competes with injectable treatments. This approval marks a significant milestone in the fight against high cholesterol, which is a leading cause of death globally.
The company is optimistic that the easier-to-take Lipfendra will appeal to high-risk patients, potentially leading to greater adoption compared to existing injectable options. This development is expected to enhance Merck's position in the cholesterol treatment market.
Merck
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Merck & Co. won US regulatory approval of a pill that rivals powerful injections for cutting dangerous cholesterol levels, betting the easier-to-take medicine will find more success with high-risk”
Bloomberg — Merck Wins FDA Approval for a Powerful New Cholesterol Pill“The speedy clearance of Lipfendra is an important milestone fo”
biopharma dive — Merck wins first approval of a PCSK9 cholesterol pill“Merck won FDA approval for the first cholesterol pill to rival powerful injectables”
quartz — Merck won FDA approval for the first cholesterol pill to rival powerful injectables
Earlier versions
- Jul 16, 11:03 AM — Merck Secures FDA Approval for Powerful New Cholesterol Pill (1/1)